Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice

International Journal of Obesity

Volumn 40, Issue 9, 2016, Pages 1416-1423

  Morrison, M C ^a,b,c   Mulder, P ^a   Salic, K ^a   Verheij, J ^d   Liang, W ^a   Van Duyvenvoorde, W ^a   Menke, A ^a   Kooistra, T ^a   Kleemann, R ^a   Wielinga, P Y ^a  

^a TNO   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AC YVAD CMK; ALPHA SMOOTH MUSCLE ACTIN; COL1A1 PROTEIN; INSULIN; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; INTERLEUKIN-1BETA-CONVERTING ENZYME INHIBITOR; SERINE PROTEINASE INHIBITOR; VIRAL PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE TOLERANCE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FIBROSIS; MALE; MOUSE; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DYSLIPIDEMIA; HYPERINSULINISM; LIPID DIET; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HYPERINSULINISM; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SERPINS; VIRAL PROTEINS;

EID: 84976317553     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.74     Document Type: Article

References (47)

1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689.
2. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59: 713-723.
3. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-171.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
5. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
7. Exley MA, Hand L, O'Shea D, Lynch L. Interplay between the immune system and adipose tissue in obesity. J Endocrinol 2014; 223: R41-R48.
8. Horng T, Hotamisligil GS. Linking the inflammasome to obesity-related disease. Nat Med 2011; 17: 164-165.
9. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54: 133-144.
10. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
11. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243: 136-151.
12. Wree A, McGeough MD, Pena CA, Schlattjan M, Li H, Inzaugarat ME et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med 2014; 92: 1069-1082.
13. Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest 2012; 92: 713-723.
14. Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One 2013; 8: e56100.
15. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014; 59: 898-910.
16. Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One 2014; 9: e115922.
17. Radonjic M, Wielinga PY, Wopereis S, Kelder T, Goelela VS, Verschuren L et al. Differential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr -/-mice. PLoS One 2013; 8: e56122.
18. Mulder P, Liang W, Wielinga PY, Verschuren L, Toet K, Havekes LMet al. Macrovesicular steatosis is associated with development of lobular inflammation and fibrosis in dietinduced non-alcoholic steatohepatitis (NASH). Inflamm Cell Signal 2015; 2: e804.
19. Lipinska K, Malone KE, Moerland M, Kluft C. Applying caspase-1 inhibitors for inflammasome assays in human whole blood. J Immunol Methods 2014; 411: 66-69.
20. Osuka A, Hanschen M, Stoecklein V, Lederer JA. A protective role for inflammasome activation following injury. Shock 2012; 37: 47-55.
21. Suzuki H, Sozen T, Hasegawa Y, Chen W, Zhang JH. Caspase-1 inhibitor prevents neurogenic pulmonary edema after subarachnoid hemorrhage in mice. Stroke 2009; 40: 3872-3875.
22. Liang W, Lindeman JH, Menke AL, Koonen DP, Morrison M, Havekes LM et al. Metabolically induced liver inflammation leads to NASH and differs from LPS-or IL-1beta-induced chronic inflammation. Lab Invest 2014; 94: 491-502.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
25. Morrison MC, Liang W, Mulder P, Verschuren L, Pieterman E, Toet K et al. Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE ∗3Leiden mice. J Hepatol 2015; 62: 1180-1186.
26. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006; 49: 450-465.
27. Rensen SS, Slaats Y, Nijhuis J, Jans A, Bieghs V, Driessen A et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol 2009; 175: 1473-1482.
28. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
29. van Diepen JA, Stienstra R, Vroegrijk IO, van den Berg SA, Salvatori D, Hooiveld GJ et al. Caspase-1 deficiency in mice reduces intestinal triglyceride absorption and hepatic triglyceride secretion. J Lipid Res 2013; 54: 448-456.
30. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
31. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-1172.
32. Xu R, Huang H, Zhang Z, Wang FS. The role of neutrophils in the development of liver diseases. Cell Mol Immunol 2014; 11: 224-231.
33. Pulli B, Ali M, Iwamoto Y, Zeller MW, Schob S, Linnoila JJ et al. Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis. Antioxid Redox Signal 2015; 23: 1255-1269.
34. Watanabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sutterwala FS et al. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol 2009; 296: G1248-G1257.
35. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
36. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010; 12: 593-605.
37. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011; 108: 15324-15329.
38. Cresto J, Lavine R, Buchly M, Penhos J, Bhathena S, Recant L. Half life of injected 125I-insulin in control and ob/ob mice. Acta Physiol Latino Am 1976; 27: 7-15.
39. Wiernsperger NF. Is non-insulin dependent glucose uptake a therapeutic alternative? Part 1: physiology, mechanisms and role of non insulindependent glucose uptake in type 2 diabetes. Diabetes Metab 2005; 31: 415-426.
40. Pilch PF, Thompson PA, Czech MP. Coordinate modulation of D-glucose transport activity and bilayer fluidity in plasma membranes derived from control and insulin-treated adipocytes. Proc Natl Acad Sci U S A 1980; 77: 915-918.
41. Vujicic M, Senerovic L, Nikolic I, Saksida T, Stosic-Grujicic S, Stojanovic I. The critical role of macrophage migration inhibitory factor in insulin activity. Cytokine 2014; 69: 39-46.
42. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014; 105: 141-150.
43. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561.
44. Tordjman J, Poitou C, Hugol D, Bouillot J-L, Basdevant A, Bedossa P et al. Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: Influence of glycemic status. J Hepatol 2009; 51: 354-362.
45. Liang W, Tonini G, Mulder P, Kelder T, van Erk M, van den Hoek AM et al. Coordinated and interactive expression of genes of lipid metabolism and inflammation in adipose tissue and liver during metabolic overload. PLoS One 2013; 8: e75290.
46. van der Heijden RA, Sheedfar F, Morrison MC, Hommelberg PP, Kor D, Kloosterhuis NJ et al. High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice. Aging 2015; 7: 256.
47. Mulder P, Morrison MC, Wielinga PY, van Duyvenvoorde W, Kooistra T, Kleemann R. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity. Int J Obes 2015; 40: 675-684.